The Clinical Safety and Effectiveness of Repaglinide in Treatment-naive Type 2 Diabetes Subjects in China. A 16-week Multicentre, Prospective, Open Label, Non-interventional Study.
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2014
At a glance
- Drugs Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms SAFE
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 07 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.